DK1745040T3 - Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater - Google Patents

Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater

Info

Publication number: DK1745040T3
Authority: DK; Denmark
Prior art keywords: azabicyclo; dopamine; modulators; receptors; derivatives useful
Prior art date: 2004-02-23

Application number

DK05707610.1T

Other languages

English (en)

Inventor

Luca Arista

Giorgio Bonanomi

Anna Maria Capelli

Federica Damiani

Fabio Romano Di

Gabriella Gentile

Dieter Hamprecht

Fabrizio Micheli

Luca Tarsi

Giovanna Tedesco

Silvia Terreni

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-23

Filing date

2005-02-21

Publication date

2010-04-12

2004-02-23 Priority claimed from GB0403990A external-priority patent/GB0403990D0/en

2004-02-24 Priority claimed from GB0404083A external-priority patent/GB0404083D0/en

2004-07-30 Priority claimed from GB0417120A external-priority patent/GB0417120D0/en

2005-02-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-04-12 Application granted granted Critical

2010-04-12 Publication of DK1745040T3 publication Critical patent/DK1745040T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK05707610.1T 2004-02-23 2005-02-21 Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater DK1745040T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0403990A GB0403990D0 (en)	2004-02-23	2004-02-23	Compounds
GB0404083A GB0404083D0 (en)	2004-02-24	2004-02-24	Compounds
GB0417120A GB0417120D0 (en)	2004-07-30	2004-07-30	Compounds
PCT/EP2005/001940 WO2005080382A1 (en)	2004-02-23	2005-02-21	Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number	Publication Date
DK1745040T3 true DK1745040T3 (da)	2010-04-12

Family

ID=34890800

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK08169934.0T DK2070922T3 (da)	2004-02-23	2005-02-21	Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexan-derivater
DK05707610.1T DK1745040T3 (da)	2004-02-23	2005-02-21	Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater
DK08169935.7T DK2060570T3 (da)	2004-02-23	2005-02-21	Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK08169934.0T DK2070922T3 (da)	2004-02-23	2005-02-21	Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexan-derivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK08169935.7T DK2060570T3 (da)	2004-02-23	2005-02-21	Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater

Country Status (25)

Country	Link
US (3)	US7855298B2 (da)
EP (3)	EP2060570B1 (da)
JP (1)	JP4960217B2 (da)
KR (1)	KR101143718B1 (da)
CN (1)	CN1946714B (da)
AR (1)	AR047890A1 (da)
AT (3)	ATE542816T1 (da)
AU (2)	AU2005215918C1 (da)
BR (1)	BRPI0507945A (da)
CA (1)	CA2557115C (da)
CY (3)	CY1109854T1 (da)
DE (1)	DE602005018190D1 (da)
DK (3)	DK2070922T3 (da)
ES (2)	ES2337590T3 (da)
HR (3)	HRP20100114T1 (da)
IL (1)	IL177184A0 (da)
MA (1)	MA28438B1 (da)
NO (1)	NO20064309L (da)
PE (1)	PE20051173A1 (da)
PL (3)	PL2060570T3 (da)
PT (3)	PT2060570E (da)
RU (1)	RU2434011C2 (da)
SI (3)	SI1745040T1 (da)
TW (1)	TW200538113A (da)
WO (1)	WO2005080382A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005215918C1 (en) *	2004-02-23	2010-01-21	Glaxo Group Limited	Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
US20070043100A1 (en)	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
GB0507602D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en)	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
JP5068747B2 (ja) *	2005-06-14	2012-11-07	グラクソグループリミテッド	ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
GB0512099D0 (en)	2005-06-14	2005-07-20	Glaxo Group Ltd	Compounds
WO2007006117A1 (en) *	2005-07-13	2007-01-18	Nicogen Inc.	Novel cyp2a6 inhibitors
CN104059013B8 (zh)	2005-07-27	2016-09-21	纽若范斯有限公司	1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
GB0517191D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
JP5237807B2 (ja) *	2005-08-22	2013-07-17	グラクソグループリミテッド	ドーパミンｄ３受容体の調節因子としてのトリアゾール誘導体
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
GB0517175D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0703387D0 (en) *	2007-02-21	2007-03-28	Glaxo Group Ltd	Novel compounds
GB0607899D0 (en) *	2006-04-03	2006-05-31	Glaxo Group Ltd	Process for preparing heterocyclic derivatives
EP2007751B1 (en) *	2006-04-03	2013-08-21	Glaxo Group Limited	Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
WO2007113258A1 (en) *	2006-04-03	2007-10-11	Glaxo Group Limited	Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
EP2007750B1 (en)	2006-04-03	2013-08-21	Glaxo Group Limited	Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
GB0608452D0 (en) *	2006-04-27	2006-06-07	Glaxo Group Ltd	Novel compounds
US20080045725A1 (en)	2006-04-28	2008-02-21	Murry Jerry A	Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds
US8138377B2 (en)	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en)	2007-06-06	2015-09-15	Neurovance, Inc.	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) *	2007-06-06	2009-03-12	Phil Skolnick	Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
GB0719234D0 (en) *	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
GB0719235D0 (en)	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
CN102816106A (zh)	2008-06-24	2012-12-12	默沙东公司	用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
SG2014014013A (en)	2008-09-22	2014-07-30	Cayman Chemical Co Inc	Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP5696142B2 (ja)	2009-06-26	2015-04-08	パナセアバイオテックリミテッド	新規アザビシクロヘキサン類
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
WO2015070253A1 (en) *	2013-11-11	2015-05-14	Euthymics Bioscience, Inc.	Novel methods
AU2016303558B2 (en)	2015-08-05	2020-08-06	Indivior Uk Limited	Dopamine D3 receptor antagonists having a bicyclo moiety
WO2019146740A1 (ja)	2018-01-26	2019-08-01	塩野義製薬株式会社	ドーパミンｄ３受容体拮抗作用を有する環式化合物
EP4168402A4 (en)	2020-06-22	2024-07-31	Corcept Therapeutics Incorporated	QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
US12115154B2 (en)	2020-12-16	2024-10-15	Srx Cardio, Llc	Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
KR20240137134A (ko)	2021-12-21	2024-09-19	코어셉트 쎄라퓨틱스 인코포레이티드	피페라진 인다졸 글루코코르티코이드 수용체 길항제
MX2024007586A (es) *	2021-12-21	2024-09-04	Corcept Therapeutics Inc	Antagonistas indazólicos bicíclicos del receptor de glucocorticoides.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR022228A1 (es) *	1999-01-12	2002-09-04	Abbott Gmbh & Co Kg	Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
GB0015562D0 (en)	2000-06-23	2000-08-16	Pfizer Ltd	Heterocycles
AU2303402A (en)	2000-11-14	2002-05-27	Smithkline Beecham Plc	Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
US6569887B2 (en) *	2001-08-24	2003-05-27	Dov Pharmaceuticals Inc.	(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
CA2463264C (en)	2001-10-22	2009-05-26	Pfizer Products Inc.	3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
RU2352568C9 (ru) *	2002-08-09	2009-06-27	Астразенека Аб	[1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
AU2005215918C1 (en) *	2004-02-23	2010-01-21	Glaxo Group Limited	Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
GB0507602D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
JP5068747B2 (ja) *	2005-06-14	2012-11-07	グラクソグループリミテッド	ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
JP5237807B2 (ja) *	2005-08-22	2013-07-17	グラクソグループリミテッド	ドーパミンｄ３受容体の調節因子としてのトリアゾール誘導体
GB0517191D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517175D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
EP2007750B1 (en) *	2006-04-03	2013-08-21	Glaxo Group Limited	Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds

2005
- 2005-02-21 AU AU2005215918A patent/AU2005215918C1/en not_active Ceased
- 2005-02-21 DE DE602005018190T patent/DE602005018190D1/de not_active Expired - Lifetime
- 2005-02-21 SI SI200530923T patent/SI1745040T1/sl unknown
- 2005-02-21 PT PT08169935T patent/PT2060570E/pt unknown
- 2005-02-21 SI SI200531398T patent/SI2070922T1/sl unknown
- 2005-02-21 JP JP2007500152A patent/JP4960217B2/ja not_active Expired - Fee Related
- 2005-02-21 RU RU2006133909/04A patent/RU2434011C2/ru not_active IP Right Cessation
- 2005-02-21 EP EP08169935A patent/EP2060570B1/en not_active Expired - Lifetime
- 2005-02-21 PL PL08169935T patent/PL2060570T3/pl unknown
- 2005-02-21 SI SI200531503T patent/SI2060570T1/sl unknown
- 2005-02-21 AR ARP050100632A patent/AR047890A1/es not_active Application Discontinuation
- 2005-02-21 DK DK08169934.0T patent/DK2070922T3/da active
- 2005-02-21 PL PL05707610T patent/PL1745040T3/pl unknown
- 2005-02-21 PT PT08169934T patent/PT2070922E/pt unknown
- 2005-02-21 ES ES05707610T patent/ES2337590T3/es not_active Expired - Lifetime
- 2005-02-21 CN CN2005800126155A patent/CN1946714B/zh not_active Expired - Fee Related
- 2005-02-21 DK DK05707610.1T patent/DK1745040T3/da active
- 2005-02-21 EP EP08169934A patent/EP2070922B1/en not_active Expired - Lifetime
- 2005-02-21 US US10/598,200 patent/US7855298B2/en not_active Expired - Fee Related
- 2005-02-21 AT AT08169935T patent/ATE542816T1/de active
- 2005-02-21 AT AT05707610T patent/ATE451364T1/de active
- 2005-02-21 AT AT08169934T patent/ATE520686T1/de active
- 2005-02-21 EP EP05707610A patent/EP1745040B9/en not_active Expired - Lifetime
- 2005-02-21 WO PCT/EP2005/001940 patent/WO2005080382A1/en not_active Ceased
- 2005-02-21 BR BRPI0507945-4A patent/BRPI0507945A/pt active Search and Examination
- 2005-02-21 TW TW094105108A patent/TW200538113A/zh unknown
- 2005-02-21 KR KR1020067016833A patent/KR101143718B1/ko not_active Expired - Fee Related
- 2005-02-21 PL PL08169934T patent/PL2070922T3/pl unknown
- 2005-02-21 DK DK08169935.7T patent/DK2060570T3/da active
- 2005-02-21 HR HR20100114T patent/HRP20100114T1/hr unknown
- 2005-02-21 PT PT05707610T patent/PT1745040E/pt unknown
- 2005-02-21 PE PE2005000205A patent/PE20051173A1/es not_active Application Discontinuation
- 2005-02-21 CA CA2557115A patent/CA2557115C/en not_active Expired - Fee Related
- 2005-02-21 ES ES08169935T patent/ES2380990T3/es not_active Expired - Lifetime
2006
- 2006-07-31 IL IL177184A patent/IL177184A0/en unknown
- 2006-08-22 MA MA29286A patent/MA28438B1/fr unknown
- 2006-09-22 NO NO20064309A patent/NO20064309L/no not_active Application Discontinuation
2009
- 2009-09-01 AU AU2009212887A patent/AU2009212887A1/en not_active Abandoned
- 2009-12-16 US US12/639,129 patent/US8263782B2/en not_active Expired - Fee Related
- 2009-12-16 US US12/639,282 patent/US8283474B2/en not_active Expired - Fee Related
2010
- 2010-03-01 CY CY20101100197T patent/CY1109854T1/el unknown
2011
- 2011-10-26 HR HR20110781T patent/HRP20110781T1/hr unknown
- 2011-11-07 CY CY20111101073T patent/CY1112011T1/el unknown
2012
- 2012-03-29 HR HR20120281T patent/HRP20120281T1/hr unknown
- 2012-04-11 CY CY20121100356T patent/CY1113029T1/el unknown

Also Published As

Publication number	Publication date
EP2070922B1 (en)	2011-08-17
ES2380990T3 (es)	2012-05-22
CA2557115A1 (en)	2005-09-01
MA28438B1 (fr)	2007-02-01
EP1745040B9 (en)	2010-06-02
HRP20120281T1 (hr)	2012-04-30
TW200538113A (en)	2005-12-01
SI1745040T1 (sl)	2010-04-30
NO20064309L (no)	2006-11-23
SI2070922T1 (sl)	2011-12-30
ATE451364T1 (de)	2009-12-15
EP1745040A1 (en)	2007-01-24
EP1745040B1 (en)	2009-12-09
US7855298B2 (en)	2010-12-21
CN1946714B (zh)	2011-06-15
IL177184A0 (en)	2006-12-10
US20100152195A1 (en)	2010-06-17
ES2337590T3 (es)	2010-04-27
US8263782B2 (en)	2012-09-11
PL2060570T3 (pl)	2012-06-29
AR047890A1 (es)	2006-03-01
WO2005080382A1 (en)	2005-09-01
DK2070922T3 (da)	2011-11-28
PL1745040T3 (pl)	2010-05-31
US20100160336A1 (en)	2010-06-24
HRP20110781T1 (hr)	2011-11-30
CY1112011T1 (el)	2015-11-04
PT2070922E (pt)	2011-11-24
CA2557115C (en)	2012-10-02
CN1946714A (zh)	2007-04-11
AU2005215918C1 (en)	2010-01-21
DE602005018190D1 (de)	2010-01-21
US8283474B2 (en)	2012-10-09
JP2007523208A (ja)	2007-08-16
PT1745040E (pt)	2010-03-08
BRPI0507945A (pt)	2007-07-24
SI2060570T1 (sl)	2012-05-31
PT2060570E (pt)	2012-05-07
PE20051173A1 (es)	2006-02-14
ATE520686T1 (de)	2011-09-15
EP2060570A3 (en)	2009-06-03
US20070142438A1 (en)	2007-06-21
EP2070922A1 (en)	2009-06-17
CY1109854T1 (el)	2014-09-10
KR101143718B1 (ko)	2012-07-05
EP2060570B1 (en)	2012-01-25
PL2070922T3 (pl)	2012-01-31
ATE542816T1 (de)	2012-02-15
AU2005215918B2 (en)	2009-06-11
HRP20100114T1 (hr)	2010-04-30
CY1113029T1 (el)	2016-04-13
AU2005215918A1 (en)	2005-09-01
DK2060570T3 (da)	2012-04-30
KR20060127991A (ko)	2006-12-13
EP2060570A2 (en)	2009-05-20
AU2009212887A1 (en)	2009-09-24
HK1103016A1 (en)	2007-12-14
RU2434011C2 (ru)	2011-11-20
JP4960217B2 (ja)	2012-06-27
RU2006133909A (ru)	2008-03-27

Publication	Publication Date	Title
DK2070922T3 (da)	2011-11-28	Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexan-derivater
DK1833799T3 (da)	2009-01-19	3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
DK2031063T3 (da)	2014-01-27	Modulatorer af duftreceptorer
DK1668014T3 (da)	2009-04-20	Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer
DK1756096T3 (da)	2009-10-26	Indolylderivater som lever-X-receptormodulatorer
DK1735286T3 (da)	2012-04-02	Tetrahydroindazoler som cannabinoidmodulatorer
DK1863474T3 (da)	2009-02-09	Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
DE602004028229D1 (de)	2010-09-02	Prostaglandin analoge als ep4 rezeptor agonisten
DK1817309T3 (da)	2010-04-19	Acetamidforbindelser som fungicider
IL194385A0 (en)	2009-08-03	Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
NO20070494L (no)	2007-03-23	Substituerte azepinderivater som serotoninreseptormodulatorer
AP2314A (en)	2011-10-31	3- 4-heteroarylcyclohexylamino cyclopentanecarboxamides as modulators of chemokine receptors.
DK1833791T3 (da)	2011-10-24	2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK2094684T3 (da)	2011-03-14	1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-on som CB1-receptor modulatorer
DE602004014772D1 (de)	2008-08-14	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
NO20074277L (no)	2007-11-23	Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
DK1928821T3 (da)	2009-03-16	Carboxamidderivater som muscarinreceptorantagonister
ZA200606661B (en)	2008-05-28	Modulation of peroxisome proliferation-activated receptors
DK1899324T3 (da)	2012-02-13	Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
DK1749001T3 (da)	2010-06-28	3-piperidinylisochroman-5-ol som dopaminagonister
ZA200606221B (en)	2010-04-28	Azabicyclo (3.1.0) Hexane derivatives useful as modulators of Dopamine D3 Receptors
HK1120194A (en)	2009-03-27	Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
DK1924580T3 (da)	2009-05-11	Ikke-steroide forbindelser, der er anvendelige som glucokortikoid-receptor modulatorer
IS8541A (is)	2006-09-19	Asabíhring (3.1.0) hexanafleiður sem eru gagnlegar sem stillar dópamín D3 viðtaka
HK1109895A (en)	2008-06-27	1,2-dihydro-spiro(3h-indole-3-4 -piperidine) compounds as modulators of the mas receptor novel